Corbus Pharmaceuticals Holdings, Inc. (CRBP) Return on equity 2016–2022
Corbus Pharmaceuticals Holdings, Inc. (CRBP) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-128.4%FY2022 · since FY2016: -224.2% → -128.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | -128.4% | -62.3 pp |
| FY2021 | -66.0% | +179.7 pp |
| FY2020 | -245.8% | +914.7 pp |
| FY2019 | -1160.4% | -958.2 pp |
| FY2018 | -202.3% | -146.2 pp |
| FY2017 | -56.1% | +168.1 pp |
| FY2016 | -224.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CRBP financial trends
CRBP RevenueCRBP Net incomeCRBP Net marginCRBP Gross profitCRBP Gross marginCRBP Operating incomeCRBP Operating marginCRBP Operating cash flowCRBP Free cash flowCRBP Capital expendituresCRBP Stock buybacksCRBP Dividends paidCRBP Total assetsCRBP Total liabilitiesCRBP Shareholders’ equityCRBP overview →